Proteins > 17-beta-hydroxysteroid dehydrogenase type 2
Page last updated: 2024-08-07 13:15:44
17-beta-hydroxysteroid dehydrogenase type 2
A 17-beta-hydroxysteroid dehydrogenase type 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P37059]
Synonyms
17-beta-HSD 2;
20 alpha-hydroxysteroid dehydrogenase;
20-alpha-HSD;
E2DH;
Estradiol 17-beta-dehydrogenase 2;
1.1.1.62;
Microsomal 17-beta-hydroxysteroid dehydrogenase;
Short chain dehydrogenase/reductase family 9C member 2;
Research
Bioassay Publications (9)
Timeframe | Studies on this Protein(%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (55.56) | 29.6817 |
2010's | 4 (44.44) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Compounds (19)
Drugs with Inhibition Measurements
Drugs with Activation Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
gsk 1016790a | Homo sapiens (human) | EC50 | 0.0490 | 1 | 1 |
Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2.Journal of natural products, , 04-28, Volume: 80, Issue:4, 2017
Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.Journal of medicinal chemistry, , Jul-24, Volume: 51, Issue:14, 2008
Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2.Journal of natural products, , 04-28, Volume: 80, Issue:4, 2017
Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.Journal of medicinal chemistry, , Jul-24, Volume: 51, Issue:14, 2008
Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2.Journal of natural products, , 04-28, Volume: 80, Issue:4, 2017
Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.Journal of medicinal chemistry, , Jul-24, Volume: 51, Issue:14, 2008
Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2.Journal of natural products, , 04-28, Volume: 80, Issue:4, 2017
Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.Journal of medicinal chemistry, , Jul-24, Volume: 51, Issue:14, 2008
Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2.Journal of natural products, , 04-28, Volume: 80, Issue:4, 2017
Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.Journal of medicinal chemistry, , Jul-24, Volume: 51, Issue:14, 2008
Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2.Journal of natural products, , 04-28, Volume: 80, Issue:4, 2017
Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.Journal of medicinal chemistry, , Jul-24, Volume: 51, Issue:14, 2008
Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2.Journal of natural products, , 04-28, Volume: 80, Issue:4, 2017
Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.Journal of medicinal chemistry, , Jul-24, Volume: 51, Issue:14, 2008
New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.Journal of medicinal chemistry, , Jan-27, Volume: 54, Issue:2, 2011
17β-HSD2 inhibitors for the treatment of osteoporosis: Identification of a promising scaffold.Bioorganic & medicinal chemistry, , Jan-15, Volume: 19, Issue:2, 2011
Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.Journal of medicinal chemistry, , Aug-14, Volume: 51, Issue:15, 2008
Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseaseJournal of medicinal chemistry, , Apr-10, Volume: 51, Issue:7, 2008
Enables
This protein enables 3 target(s):
Target | Category | Definition |
estradiol 17-beta-dehydrogenase [NAD(P)] activity | molecular function | Catalysis of the reaction: estradiol-17-beta + NAD(P)+ = estrone + NAD(P)H + H+. The activity can use NAD+ or NADP+ as the acceptor. [EC:1.1.1.62] |
17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase activity | molecular function | Catalysis of the reaction: NAD(P)+ + 17-alpha,20-alpha-dihydroxypregn-4-en-3-one = NAD(P)H + H+ + 17-alpha-hydroxyprogesterone. [EC:1.1.1.149, MetaCyc:1.1.1.149-RXN] |
testosterone dehydrogenase (NAD+) activity | molecular function | Catalysis of the reaction: testosterone + NAD+ = androst-4-ene-3,17-dione + NADH. [EC:1.1.1.239] |
Located In
This protein is located in 1 target(s):
Target | Category | Definition |
endoplasmic reticulum membrane | cellular component | The lipid bilayer surrounding the endoplasmic reticulum. [GOC:mah] |
Active In
This protein is active in 1 target(s):
Target | Category | Definition |
intracellular membrane-bounded organelle | cellular component | Organized structure of distinctive morphology and function, bounded by a single or double lipid bilayer membrane and occurring within the cell. Includes the nucleus, mitochondria, plastids, vacuoles, and vesicles. Excludes the plasma membrane. [GOC:go_curators] |
Involved In
This protein is involved in 6 target(s):
Target | Category | Definition |
in utero embryonic development | biological process | The process whose specific outcome is the progression of the embryo in the uterus over time, from formation of the zygote in the oviduct, to birth. An example of this process is found in Mus musculus. [GOC:go_curators, GOC:mtg_sensu] |
placenta development | biological process | The process whose specific outcome is the progression of the placenta over time, from its formation to the mature structure. The placenta is an organ of metabolic interchange between fetus and mother, partly of embryonic origin and partly of maternal origin. [GOC:add, ISBN:068340007X] |
estrogen biosynthetic process | biological process | The chemical reactions and pathways resulting in the formation of estrogens, C18 steroid hormones that can stimulate the development of female sexual characteristics. Also found in plants. [ISBN:0198506732] |
androgen metabolic process | biological process | The chemical reactions and pathways involving androgens, C19 steroid hormones that can stimulate the development of male sexual characteristics. [ISBN:0198506732] |
response to retinoic acid | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a retinoic acid stimulus. [GOC:sl] |
steroid metabolic process | biological process | The chemical reactions and pathways involving steroids, compounds with a 1,2,cyclopentanoperhydrophenanthrene nucleus. [ISBN:0198547684] |